Researchers have been studying psilocybin in an attempt to discover any benefits the substance holds that may be useful to migraine sufferers. Psilocybin is found in magic mushrooms and is the main active ingredient responsible for the psychedelic effects mushrooms produce. The findings, which were reported in “Neurotherapeutics,” offer evidence that psilocybin may provide long-lasting therapeutic benefits to individuals who suffer from migraines.
Over the years, anecdotal reports have claimed that psilocybin may lessen the symptoms of migraines. However, there hasn’t been enough scientific evidence to support these reports. This recently published study is the first placebo-controlled, double-blind study that explores whether the psychedelic substance influences migraines.
Yale School of Medicine assistant professor of neurology Emmanuelle A.D. Schindler, who is the author of the study, stated that she saw the need for more treatment options for headache disorders — in particular migraines — having studied the neuropharmacology of psychedelics.
She noted that her curiosity on whether psychedelics could be used as an alternative treatment and assist researchers in better understanding the pathology of headache disorders originated from reports showing that patients who suffered from various headache disorders recorded lasting improvements after the administration of one or more psilocybin doses, as well as other psychedelics.
For the research, three men and seven women who suffered from frequent migraines received a placebo capsule then, almost a fortnight later, received a low-dose psilocybin capsule. Neither the research staff nor participants knew which capsule contained psilocybin and which contained the placebo.
Before the placebo dose had been administered, the study participants were asked to keep a daily diary of their headache symptoms; the diary was to be kept until a fortnight after they’d received the psilocybin dose.
The researchers found that psilocybin was linked to a substantial decrease in migraine frequency in comparison with the placebo 14 days after the capsule had been administered. In addition, psilocybin was also linked to decreases in both functional impairments related to migraines and headache pain severity. These findings align with a separate study, which was published by Schindler and her fellow researchers in 2015.
In the 2015 study, the researchers had discovered that hallucinogenic mushrooms were being utilized in the treatment and prevention of cluster headaches, which are a type of headache disorder. They noted that magic mushrooms were found to be more effective in managing cluster headaches in comparison with standard treatments. Despite these promising discoveries, Schindler notes that more research needs to be conducted.
Firms such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) that are also doing research with the objective of developing psilocybin-based medicines are likely to add to what is known about the therapeutic potential of this and other active compounds in psychedelics.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.